Sam Brusco, Associate Editor05.12.22
BD (Becton, Dickinson and Company) launched it new BD COR MX instrument, an automated, high-throughput infectious disease molecular diagnostics platform, in the U.S. after earning U.S. Food and Drug Administration (FDA) clearance.
The new BD COR MX analytic instrument is used with the company’s ND COR system. The first available test on the new system is the BD CTGCTV molecular assay, which spots the three most prevalent non-viral STIs: Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC) and Trichomonas vaginalis (TV).
The system eliminates the need to sort specimens so lab techs have minimal interaction with them, freeing up lab techs’ time for other critical processes.
1,700 specimens can be loaded, with onboard capacity for reagents and samples allowing over seven hours of continuous system processing. The system can deliver up to 1,000 sample results in a day, eliminating traditionally required multiple manual interactions. Dual DNA targets for CT and GC detection together in the same sample and assay help to reduce false positives, as well.
"Even before COVID-19, clinicians and laboratory technicians were faced with increasing workloads and patient needs, and now those challenges have been amplified significantly by the ongoing staffing shortages and further increased workloads caused by the pandemic," Brooke Story, president of Integrated Diagnostic Solutions for BD told the press. "By automating labor-intensive and mundane error-prone processes, the BD COR MX/PX System allows lab technicians and clinicians to focus on higher value work."
Samples can be self-collected in a clinical setting via vaginal/endocervical swab, urine, and liquid-based cytology.
The new BD COR MX analytic instrument is used with the company’s ND COR system. The first available test on the new system is the BD CTGCTV molecular assay, which spots the three most prevalent non-viral STIs: Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC) and Trichomonas vaginalis (TV).
The system eliminates the need to sort specimens so lab techs have minimal interaction with them, freeing up lab techs’ time for other critical processes.
1,700 specimens can be loaded, with onboard capacity for reagents and samples allowing over seven hours of continuous system processing. The system can deliver up to 1,000 sample results in a day, eliminating traditionally required multiple manual interactions. Dual DNA targets for CT and GC detection together in the same sample and assay help to reduce false positives, as well.
"Even before COVID-19, clinicians and laboratory technicians were faced with increasing workloads and patient needs, and now those challenges have been amplified significantly by the ongoing staffing shortages and further increased workloads caused by the pandemic," Brooke Story, president of Integrated Diagnostic Solutions for BD told the press. "By automating labor-intensive and mundane error-prone processes, the BD COR MX/PX System allows lab technicians and clinicians to focus on higher value work."
Samples can be self-collected in a clinical setting via vaginal/endocervical swab, urine, and liquid-based cytology.